No Data
J&J Multiple Myeloma Drug Talvey Cuts Mortality Risk by up to 53% in Late-stage Trial
Express News | J&J - Submits Sbla to FDA and Type II Variation to EMA for Talvey Combination
Express News | New Talvey® (Talquetamab-Tgvs) Plus Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj) Data Demonstrate the Strength of a Bispecific Combination in Earlier-Line Relapsed or Refractory Multiple Myeloma
CMS Proposes Making Medicare Drug Price Negotiations Permanent
Best ETFs to Invest In, According to AI Analyst, 6/12/2026
Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD), Johnson & Johnson (JNJ) and Phreesia (PHR)